Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
Operating Income
Antisense Therapeutics Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Antisense Therapeutics Ltd
ASX:ANP
|
Operating Income
-AU$11.4m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-17%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Income
-AU$165.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Income
AU$204.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Income
-AU$18.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-28%
|
|
Probiotec Ltd
ASX:PBP
|
Operating Income
AU$20m
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Income
-AU$26.4m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Antisense Therapeutics Ltd's Operating Income?
Operating Income
-11.4m
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Operating Income amounts to -11.4m AUD.
What is Antisense Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-17%
Over the last year, the Operating Income growth was -96%. The average annual Operating Income growth rates for Antisense Therapeutics Ltd have been -24% over the past three years , -37% over the past five years , and -17% over the past ten years .